Catheter-Associated Urinary Tract Infections (CAUTIs or just catheter UTI’s) can be extremely virulent bacterial infections which are very difficult to treat and eradicate.
With a 5% cumulative increased risk of bacteriuria per day of a fitted catheter, we can assume that within 1 month of having a catheter a patient has developed some form of a bacterial infection. CAUTIs are the most common cause of gram-negative bacteraemia in hospitalised patients and are responsible for 40% of Hospital-Acquired Infections (HAIs).  Biofilms on the indwelling catheter have been shown to be the main cause of CAUTI and can also be responsible for the blocking of catheters. 
Recurrent UTIs, can lead to the total cost of episodes per annum across the UK to be greater than £1 billion. 
‘A healthcare associated Gram-negative BSI is a positive blood culture for a Gram-negative pathogen in patients who received healthcare in the community or hospital in the previous 28 days’ (Public Health England)
CAUTIs cost the NHS a staggering amount each year, regularly leading to antibiotic prescription.
In the growing fight against antibiotic resistance it is key to find novel infection prevention strategies and to dramatically reduce the amount of antibiotics prescribed.
NHS 5 Year Forward Plan
The NHS ‘5 Year Forward Plan’ was devised to set out a clear direction for the NHS, showing why change is needed and how it can be achieved. There are several points in this plan which directly relate to infections prevention, and how this can contribute to an improved NHS.
The UroShield is a small, external medical device which clips onto both urethral and suprapubic catheters and generates low-frequency ultrasonic Surface Acoustic Waves (SAW).
These waves run longitudinally along the full length of the catheter, both on the external surface and inside the catheter lumen. The action of the wave to constantly but subtly vibrate the catheter, which isn’t felt by the patient, prevents bacteria from docking and adhering to the catheter and reaching the reversible adherence stage.
This therefore prevents the biofilm formation and in turn helps to prevent infections from developing, as well as reducing catheter blockages and incrustation.
UroShield has been
Tried and Tested
We have worked with Healthcare professionals to provide robust clinical studies on the impact of catheter-related problems.